At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age.
In Brief
A Phase 3 clinical trial evaluating Meningococcal ACWY Polysaccharide Vaccine, MenACWY CRM (19 to 55 years), and 2 other interventions for Meningococcal Meningitis and Meningococcal Infections. Completed, enrolled 2,831 participants across 2 sites in 2 countries.
Detailed Summary
This study will evaluate the safety and immune response of Novartis Meningococcal ACWY conjugate vaccine in healthy adolescents and adults.
Study Details
Timeline
Interventions
One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.